Top

Annals of Hematology

Published in:

01-02-2018 | Letter to the Editor

PET-positive bone lesion due to Langerhans cell histiocytosis after BEACOPP therapy for Hodgkin lymphoma: how anamnesis, histopathological accuracy, and molecular analysis could resolve a clinical dilemma

Authors: Simon Haefliger, Michel Bihl, Fatime Krasniqi, Alexandar Tzankov

Published in: Annals of Hematology | Issue 2/2018

Excerpt

Dear Editor, …

Berres ML, Merad M, Allen CE (2015) Progress in understanding the pathogenesis of Langerhans cell histiocytosis: back to Histiocytosis X? Br J Haematol 169:3–13. https://doi.org/10.1111/bjh.13247 CrossRefPubMed

Badalian-Very G, Vergilio JA, Degar BA, MacConaill LE, Brandner B, Calicchio ML, Kuo FC, Ligon AH, Stevenson KE, Kehoe SM, Garraway LA, Hahn WC, Meyerson M, Fleming MD, Rollins BJ (2010) Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood 116:1919–1923. https://doi.org/10.1182/blood-2010-04-279083 CrossRefPubMedPubMedCentral

Brown NA, Furtado LV, Betz BL, Kiel MJ, Weigelin HC, Lim MS, Elenitoba-Johnson KS (2014) High prevalence of somatic MAP2K1 mutations in BRAF V600E–negative Langerhans cell histiocytosis. Blood 124:1655–1658. https://doi.org/10.1182/blood-2014-05-577361 CrossRefPubMed

Pina-Oviedo S, Medeiros LJ, Li S, Khoury JD, Patel KP, Alayed K, Cason RC, Bowman CJ, Yin CC (2017) Langerhans cell histiocytosis associated with lymphoma: an incidental finding that is not associated with BRAF or MAP2K1 mutations. Mod Pathol 30:734–744. https://doi.org/10.1038/modpathol.2016.235 CrossRefPubMed

Christie LJ, Evans AT, Bray SE, Smith ME, Kernohan NM, Levison DA, Goodlad JR (2006) Lesions resembling Langerhans cell histiocytosis in association with other lymphoproliferative disorders: a reactive or neoplastic phenomenon? Hum Pathol 37:32–39. https://doi.org/10.1016/j.humpath.2005.08.024 CrossRefPubMed

Mesguich C, Cazeau AL, Bouabdallah K, Soubeyran P, Guyot M, Milpied N, Bordenave L, Hindié E (2016) Hodgkin lymphoma: a negative interim-PET cannot circumvent the need for end-of-treatment-PET evaluation. Br J Haematol 175:652–660. https://doi.org/10.1111/bjh.14292 CrossRefPubMed

Naumann R, Beuthien-Baumann B, Fischer R, Kittner T, Bredow J, Kropp J, Ockert D, Ehninger G (2002) Simultaneous occurrence of Hodgkin’s lymphoma and eosinophilic granuloma: a potential pitfall in positron emission tomography imaging. Clin Lymphoma Myeloma Leuk 3:121–124. https://doi.org/10.3816/CLM.2002.n.019 CrossRef

Shin MS, Buchalter SE, Ho KJ (1994) Langerhans cell histiocytosis associated with Hodgkin’s disease: a case report. J Natl Med Assoc 86:65–69PubMedPubMedCentral

Egeler RM, Neglia JP, Arico M, Favara BE, Heitger A, Nesbit ME, Nicholson HS (1998) The relation of Langerhans cell histiocytosis to acute leukaemia, lymphomas, and other solid tumors. The LCH-Malignancy Study Group of the Histiocyte Society Hematol Oncol Clin North Am 12:369–378. https://doi.org/10.1016/S0889-8588(05)70516-5 CrossRef

10.

Natoli A, Lüpertz R, Merz C, Müller WW, Köhler R, Krammer PH, Li-Weber M (2013) Targeting the IL-4/IL-13 signaling pathway sensitizes Hodgkin lymphoma cells to chemotherapeutic drugs. Int J Cancer 133:1945–1954. https://doi.org/10.1002/ijc.28189 CrossRefPubMed

11.

Loghavi S, Khoury JD (2017) Langerhans cell histiocytosis in a patient with hairy cell leukemia: a tale of divergence. Blood 129:1563. https://doi.org/10.1182/blood-2016-11-749374 CrossRefPubMed

12.

Ryland GL, Jones K, McBean M, Khot A, Seymour JF, Blombery P (2017) Comprehensive genomic characterization dissects the complex biology of a case of synchronous Burkitt lymphoma and myeloid malignancy with shared hematopoietic ancestry. Leuk Lymphoma 9:1–4. https://doi.org/10.1080/10428194.2017.1361029 CrossRef

Title: PET-positive bone lesion due to Langerhans cell histiocytosis after BEACOPP therapy for Hodgkin lymphoma: how anamnesis, histopathological accuracy, and molecular analysis could resolve a clinical dilemma
Authors: Simon Haefliger
Michel Bihl
Fatime Krasniqi
Alexandar Tzankov
Publication date: 01-02-2018
Publisher: Springer Berlin Heidelberg
Published in: Annals of Hematology / Issue 2/2018
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI: https://doi.org/10.1007/s00277-017-3145-0

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

PET-positive bone lesion due to Langerhans cell histiocytosis after BEACOPP therapy for Hodgkin lymphoma: how anamnesis, histopathological accuracy, and molecular analysis could resolve a clinical dilemma

Excerpt

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 2/2018

Correlation study between osteoporosis and hematopoiesis in the context of adjuvant chemotherapy for breast cancer

HCV load as a possible prognostic factor in patients with HCV-related DLBCL

Liver fibrosis alleviation after co-transplantation of hematopoietic stem cells with mesenchymal stem cells in patients with thalassemia major

Simultaneous point-of-care detection of anemia and sickle cell disease in Tanzania: the RAPID study

Expression of PD-1 and PD-L1 on cytotoxic T lymphocytes and immune deficiency in a patient with adult T cell leukemia/lymphoma

Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO)

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page